<DOC>
	<DOCNO>NCT01189422</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability , pharmacodynamics ( PD ) pharmacokinetics ( PK ) subcutaneously administer teplizumab adult relatively recent onset T1DM , great 12 week less 52 week presentation first sign symptom disease physician prior randomization .</brief_summary>
	<brief_title>Subcutaneous Administration Teplizumab Adults With Type 1 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<criteria>Randomization 12 week within 12 month first doctor visit symptom sign diabetes Diagnosis type 1 diabetes mellitus Currently receive insulin therapy Detectable fasting stimulate Cpeptide level screen One positive autoantibody test result screening : Isletcell autoantibody ( ICA512 ) /islet antigen2 ( IA2 ) , Glutamic acid decarboxylase ( GAD ) autoantibody , Insulin autoantibodies Any medical condition , opinion investigator , would interfere safe completion trial Previous treatment monoclonal antibody Current treatment oral antidiabetic agent Evidence active infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Type 1 Diabetes Mellitus</keyword>
	<keyword>T1DM</keyword>
</DOC>